Two mammary gland phenotypes were detected in pregnant MMTV-cyclin D2 transgenic mice; line D2 -53 exhibited a lack of alveologenesis and failure to nurse, whereas line D2 -58 featured a reduction in alveologenesis, but retained normal nursing behavior. In pregnant mammary glands, cyclin D2 protein levels were twofold (P50.107) and 3.8-fold (P50.0076) higher in line D2 -58 and D2 -53, respectively, compared to wild type. Concomitantly with the increase in cyclin D2 was a fivefold decrease in cyclin D1 hyper-phosphorylated isoform in mammary glands of pregnant cyclin D2 -58 mice. Because cyclin D1 is a critical molecule in normal mammary lobuloalveolar development, these data suggest that overexpression of cyclin D2 may block mammary lobuloalveolar development through inhibition of cyclin D1 phosphorylation. During mammary gland development, p27 kip1 protein level oscillated in a similar profile in wild type and cyclin D2 transgenic mice, but was consistently higher in the cyclin D2 mice suggesting that p27 kip1 functions downstream of cyclin D2. The ratio of p27 kip1 -cdk4/p27 kip1 -cdk2 was 6.5-fold (P50.0003) higher in cyclin D2 mammary glands compared to wild type in pregnant animals. This ratio reversed to 2.2-fold (P50.005) higher in wild type compared to cyclin D2 mammary glands in involution suggesting that overexpression of cyclin D2 moderately induced apoptosis during pregnancy but accelerated involution. Collectively, the effects of cyclin D2 overexpression on mammary gland development during pregnancy and involution are attributed to two major factors, altered p27 kip1 protein level and inhibition of cyclin D1 phosphorylation.
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Introduction
In mammalian cells, cell proliferation is regulated in an orderly fashion from G1 to S-to G2/M by a subset of cell cycle genes that encode cyclin-dependent kinases (cdks) and the proteins that regulate their behavior, cyclins and cdk inhibitors. Analysis of gene expression has indicated that phase-specific oscillations in the abundance of some of these proteins are responsible, in part, for the orderly and linear progression of cells through key cell cycle checkpoints (O'Connell and Nurse, 1994; Sherr, 1994; Hartwell and Weinert, 1989 ). An important cell cycle checkpoint called the restriction point is located at a position just prior to the onset of DNA synthesis (Murray, 1992) . Three D-type cyclins (D1, D2, and D3) are expressed in G1 phase of the cell cycle and depending on cell lineage, various combinations of Dtype cyclins are induced by mitogens (O'Connell and Nurse, 1994; Sherr, 1994) . D-type cyclins form complexes with and activate cdk2, -4, and -6 during the G1 phase of the cell cycle (Sherr, 1994) . A key substrate for G1 cyclin/cdk complexes is the retinoblastoma protein, pRb. Phosphorylation of pRb, a tumor suppressor gene product, has been attributed to cyclin/cdk complexes and implicated in the regulation of proliferation in mammalian cells (O'Connell and Nurse, 1994; Hunter and Pines, 1994; Weinberg, 1995; Nivins, 1992) . Thus, phosphorylation of pRb blocks its ability to suppress the activity of S phase promoting transcription factors such as E2F (O'Connell and Nurse, 1989; Weinberg, 1995; Nivins, 1992) .
In addition to their positively regulating cell cycle, D-type cyclins have been implicated in cell transformation and neoplasia in human and mouse. Cyclin D1 overexpression or amplification was described in a number of tumor types including lymphomas Withers et al., 1991) , breast cancer Lammie et al., 1991; Buckley et al., 1993) and thyroid carcinoma (Motpokura et al., 1991; . Up-regulation of cyclin D2 has been implicated in human gastric carcinoma (Yosogawa et al., 1998) , ovarian granulosa cell tumors (Siciniski et al., 1996) , a subset of breast cancers and in male-germ cell malignancies (Houldsworth et al., 1997) .
The function of D-type cyclins has also been studied in D-type cyclin-deficient mice. Cyclin D1 null mice presented neurological impairment, as well as deficient development of retina and mammary glands (Fantl et al., , 1999 , while cyclin D2-deficient mice showed alterations in gonadal cell proliferation with no specific effects on the mammary gland (Siciniski et al., 1996) . Taken together, these data suggest tissue-specific functions of D-type cyclins.
Initially, several reports assigned redundant roles to the three members of D-type cyclins, but in the last few years, it has become evident that each member plays a specific role and is differentially expressed in various tissues (Sherr, 1994) . Recently, it has been reported that Myc induced cyclin D1 and D2 protein synthesis and this in turn contributed to the sequestration of the cell cycle inhibitor p27 kip1 thereby facilitating cell cycle entry into the S phase (Perez-Roger et al., 1999) . Furthermore, in B-lymphocytic tumors, transcriptional activation of c-myc by chromosomal translocation promotes the expression of cell cycle activators such as cyclin D2, E and cdk4 (Janz et al., 1995; Pajic et al., 2000) .
Apart from the positive roles that D-type cyclins play in cell cycle progression, a number of recent studies have shown that D-type cyclins also perform cdk-independent functions and, in certain cell types, even prevent cdks from being activated. For example, the overexpression of cyclin D1 alone inhibited fibroblast entry into the S phase (Pagano et al., 1994; Pestka et al., 1987) ; overexpression of D1 in mouse mammary epithelial cells also delayed S phase entry and growth (Han et al., 1995) . This appears to be due to D1-mediated induction of the cell cycle inhibitor p27 kip1 (Han et al., 1996) . In our previous study, we have reported a similar observation, where HMBA, a hybrid polar compound that induces cell growth arrest and differentiation, resulted in overexpression of cyclin D2 and p27 kip1 concomitantly with G1 cell growth arrest in mouse mammary tumor cells (Said and Medina, 1998) . In an in vivo study, we also reported that cyclin D2/cdk4 protein level increased during the early preneoplastic stage of mammary tumorigenesis but both D2/cdk4 protein level and kinase activity were diminished during late stages of mammary tumorigenesis. Concomitantly, D1/cdk4 and D1/cdk2 and their kinase activities increased suggesting that the inactive D2/cdk4 complex is either dispensable or its absence is a contributary factor for late stages of mammary tumorigenesis . In support of the latter idea, recent studies have demonstrated that 50% of the human breast cancers were associated with silencing of cyclin D2 gene expression by hypermethylation of its promoter (Evron et al., 2001) .
The effects that follow overexpression of cyclin D2 in mammary epithelial cells are not understood. We developed the MMTV-cyclin D2 transgenic mouse to study the effect of cyclin D2 overexpression on cell cycle machinery and on morphogenesis of the mammary gland during development.
Results

Generation of cyclin D2 transgenic mice
The construct used to generate transgenic mice is depicted in Figure 1a . The 2.334 kb BamHI MMTVLTR directs mammary gland specific expression (Sinn et al., 1987) . As expected, this promoter drives cyclin D2 protein expression in mammary epithelial HC11 cells in a hormone dependent element fashion with the treatment of Dexamethasone (data not shown). Three cyclin D2-positive mice (D50, D53 and D58) were identified by PCR (Figure 1b ) and confirmed by Southern blot analysis (Figure 1c) . These results permitted the selection of three mice as first transgenic founders cyclin D2. An expected two main bands of 1253 and 2175 bp were observed that correspond to the transgenic signal. Because most transgenes integrate into the genome in a head-to-tail or a tail-to-head or rarer in a head-to-head or tail-totail configuration, we can get extra bands. In this case, we think the MMTV-D2 transgene integrated in a head-to-tail configuration. Therefore, the upper band probably corresponds to a NcoI -NcoI fragment that stretched from one transgene to the next that hybridized by the 640 bp KCR probe (BamHI-EcoRI) ( Figure 1c ). As the positive control provides an approximate copy number of cyclin D2 incorporation, 10 and 100 pg of the MMTV-Cyc-D2 plasmid digested with BglII and NcoI represented approximately 1 and 10 copies, respectively. The 1.4 and 2.9 kb bands (arrows) correspond to the digested plasmid bands (Figure 1c) . From PCR and Southern blot analysis, it appeared that more copies of the cyclin D2 transgene were incorporated in the genome of cyclin D2 -53 compared to D2 -50 or D2 -58 founder mice.
To determine whether the approximate copy number of cyclin D2 transgene incorporated in the genome corresponds to the protein level of each group, equivalent amounts of protein extracts from mammary glands of multiple pregnant wt, cyclin D2 -53 and D2 -58 mice were examined by Western blot analysis. The cyclin D2 protein level was twofold (P50.107) and 3.8-fold (P50.0076) higher in line D2 -58 and D2 -53, respectively, compared to wild type glands (Figure 2) . The cyclin D2 -53 (high cyclin D2 expresser) and the cyclin D2 -58 (low cyclin D2 expresser) mice were selected to cross with cyclin D2 FVB males to expand each line. PCR and Southern blot analysis were performed on the F0 and F1 founders and later generations were routinely genotyped by PCR.
Morphogenesis in mammary glands of cyclin D2 transgenic mice during development
The mammary glands of wt and cyclin D2 transgenic mice exhibited similar morphogenesis in 12-weeks-old virgin mice. However, mammary glands of 14 -16 days pregnant cyclin D2 -53 transgenic line exhibited lack of alveolar differentiation, occasionally presented with thick ducts and failure to nurse (Figure 3) . The mammary glands of the cyclin D2 -58 line at midpregnancy were able to differentiate but developed fewer and smaller lobules and showed fewer fat droplets as compared to wt (Figures 3 and 4) . Although cyclin D2 -58 mice appeared to be able to nurse normally, the lobuloalveolar structures were underdeveloped as they comprised fewer secretory cells and were unable to expand to the same size during lactation as in the wt (Figures 3 and 4) . At 10 days of involution, the cyclin D2 -58 mammary glands showed accelerated involution compared to the wt (Figure 3 ). These data suggest that the blockage of alveologenesis observed in mammary glands of midpregnant cyclin D2 -53 mice and the underdevelopment in the cyclin D2 -58 mice may be related to the levels of cyclin D2 protein expression in each line depending on number of copies of cyclin D2 transgene that had been incorporated in each line's genome (Figures 1b,c and 2 ).
Cell proliferation and apoptosis in cyclin D2 transgenic mammary glands during development
To study the effect of cyclin D2 overexpression on cell proliferation, we examined the fraction of cells that are actively proliferating by BrdU incorporation in the cyclin D2 and wt mammary glands. The BrdU positive cells were counted on multiple animals at each stage of development. On serial sections, positive cells were also counted by TUNEL assay. The ) were digested with NcoI and BglII and probed with a 640 bp BamHI -EcoRI probe as depicted. The probe hybridizes to the 1253 and 2175 bp bands and that indicates a positive signal for a transgenic line. For an estimation of copy number, approximately one copy (10 pg) and 10 copies (100 pg) of transgenic plasmid DNA was added to non-transgenic tail DNA and similarly digested with NcoI and BglII. Two bands were detected at 1253 and 5135 bp by the probe Figure 2 Cyclin D2 protein levels in mammary glands of pregnant wt and cyclin D2 transgenic lines. Western blot analysis of equivalent amounts of 200 mg protein extracts from mammary glands of pregnant wt and the high expresser (cyclin D2 -53) and low expresser (cyclin D2 -58) mice carrying the MMTV-cyc-D2 transgene were separated by 12.5% SDS -PAGE and blotted to a nitrocellulose membrane. A positive control of 200 mg protein from cyclin D2-58 tumor was included. Primary antibody against cyclin D2, mouse cyclin D2-Ab-2 monoclonal antibody and actin for equal loading were used. The levels of cyclin D2 were quantified with Molecular Dynamics SF densitometer and were normalized with actin percentage of cell proliferation was not altered in the respective virgin mice but was increased by 2.7-fold (P40.005) in mammary glands of pregnant cyclin D2 mice compared to wt ( Figure 5 ). While localization of BrdU was observed predominantly in the lobuloalveolar epithelium in the wt pregnant gland, the profound increase in cell proliferation occurred in both the ductal and the small lobular epithelium of cyclin D2 mammary glands ( Figure 5 ). Nonetheless, the lobuloalveolar structures appeared to be underdeveloped in size and number in cyclin D2 mammary glands of pregnant mice compared to wt ( Figure 5 ). Collectively, these data suggest that though overexpression of cyclin D2 may induce cell proliferation, normal differentiation and lobuloalveolar development appeared to be blocked. At 10 days of lactation, no incorporation of BrdU was observed in either the wt or cyclin D2 transgenic mammary glands. At 10 days of involution, the extent of proliferating cells was 5 and 2.8% in the wt and cyclin D2 mammary glands, respectively ( Figure 5 ), where the difference was significant (P40.05). These data indicated that the increase in cell proliferation rate in cyclin D2 mammary gland reflected by the level of BrdU incorporation was stimulated only at mid-pregnancy, while significantly reduced at 10 days of involution.
Because of the discordance between the extent of lobuloalveolar development and the BrdU-labeling indices, it was of interest to examine the possible effect(s) of cyclin D2 overexpression on apoptosis. The frequency of apoptosis was 2% in the mammary glands of pregnant cyclin D2 mice, whereas apoptotic activity was undetectable in the wt ( Figure 6 ). Interestingly, the apoptotic cells were localized predominantly in the lobular epithelium, which could be a significant factor for the reduced size of the lobules in the cyclin D2 mammary glands. It is well known that apoptotic activity increases during involution and therefore, it was of interest to Figure 4 Difference in the histological profile between wt and cyclin D2 -58 mammary glands. Representative paraffin-sections of mammary glands from mid-pregnant wt and cyclin D2 -58 mice (a) and (b), respectively, and at 10-day lactation (c) and (d), respectively, were stained with hematoxylin and eosin. Note differences in size of lobules that make the lobuloalveolar structures in pregnant and lactating mammary glands. Also the lack of lipid globules in the pregnant cyclin D2 compared to wt (arrow). The marked differences in the development of the secretory alveoli in the lactating mammary gland are illustrated in panels (c) and (d) . (206 magnification) examine whether mammary glands of cyclin D2 mice were also more sensitive to the induction of apoptosis at 10 days of involution. We observed 30% (P40.005) increase in the apoptotic cells in the involuted cyclin D2 mammary glands compared to wt ( Figure 6 ). Collectively, these data indicate that overexpression of cyclin D2 in the mammary epithelium limits normal lobular size and/or number or even blocks alveologenesis in pregnancy depending on the level of cyclin D2 protein expressed in the mammary epithelium. The decrease in BrdU and the increase in apoptosis may explain why mammary glands of cyclin D2 mice appear more involuted after cessation of lactation.
Effect of cyclin D2 overexpression on cell cycle components during mammary gland development
Due to the availability of tissues at all stages of mammary gland development, most of the data on cell cycle were obtained from wt and cyclin D2 -58 phenotype, unless stated otherwise. Because cyclin D1 is a critical molecule in mammary alveologenesis (Siciniski and Weinberg, 1997; Fantl et al., 1999) , we measured the levels of cyclin D1 and D2 during mammary gland development in both wt and cyclin D2 transgenic mice. Cyclin D2 levels are barely detectable in the wt type at all stages of development as shown in Figure 7 , whereas the cyclin D1 levels peaked during pregnancy and declined in involution. Although cyclin D2 was barely detectable in the wt mammary glands by Western blot analysis (Figure 7) , it was detectable by immunohistochemical staining in few ducts in wt virgin and was predominantly localized in the myoepithelial cells (arrow - Figure 8a ). These data suggest that in normal mammary glands, cyclin D2 may have some kind of 'protective' function in the myoepithelial cells and may not play a direct role in mammary luminal epithelial cell differentiation.
The general patterns of cyclin D1 and D2 expression were similar in the cyclin D2 transgenic mice throughout development. Cyclin D2 was undetectable in the virgin mammary gland of cyclin D2 transgenic mice measured by Western blot analysis (Figure 7 ), however it was detectable weakly in myoepithelial cells and in a few predominantly luminal epithelial cells in every duct (arrow - Figure  8 ). The protein level of cyclin D2 increased 25-fold at mid-pregnant compared to virgin and declined during lactation, then continued at low levels during involution as measured by Western blot analysis (Figure 7 ). These data were confirmed by a strong cyclin D2 signal in greater than 50% of the luminal cells in pregnant glands and by a weak signal in a majority of cells in involuting cyclin D2 glands examined by immunohistochemical staining ( Figure  8 ). However, in comparison to the wt, the total level of cyclin D1 (hyper-and hypo-phosphorylated isoforms) decreased threefold and hyper-phosphorylated (upper band) cyclin D1 isoform alone decreased fivefold (Figure 7 ) in the mammary glands of pregnant cyclin D2 mice. The phosphorylation level was judged by the slow migration of the hyperphosphorylated isoform of cyclin D1 on the gel. Previous studies reported that the insoluble cyclin D1 fraction (hyper-phosphorylated isoform) was tyrosine and serine-phosphorylated and was tightly bound with the nuclear structures in mid and late G1, while the soluble fraction of cyclin D1 is phosphorylated on only tyrosine and localized predominantly in the cytoplasm (Scovassi et al., 1997) . The level of the hyper-phosphorylated cyclin D1 isoform decreased dramatically in both wt and D2 transgenic lactating mammary glands and maintained at low levels during involution (Figure 7 ). These data suggest that overexpression of cyclin D2 has a profound effect on cyclin D1 phosphorylation during pregnancy.
Several in vitro studies have reported that cyclin D1 overexpression after stable transfection of different cell lines or overexpression of cyclin D2 resulted in cell growth arrest due to an up-regulation of p27 kip1 (Han et al., 1996; Jiang et al., 1993; Meyyappan et al., 1998) . We examined the levels of p27 kip1 in mammary glands of cyclin D2 transgenic mice in comparison to wt during development. The p27 kip1 protein level was 2.4-fold higher in the virgin mammary glands of cyclin D2 mice compared to virgin wt as examined by Western blot analysis ( Figure 7) and was confirmed by a 17.5-fold increase in the total score of p27 kip1 staining as measured immunohistochemically (Figure 8 ). Although cyclin D2 protein level was below the detection limit in the wt and cyclin D2 virgin mammary glands measured by Western blot analysis (Figure 7) , nonetheless, the total score of cyclin D2 measured immunohistochemically was 2.5-fold higher in the virgin cyclin D2 mammary gland compared to the wt (Figure 8 ). The and actin were quantified. The bar graph represents the total protein levels of cyclin D1, D2 and p27 kip1 in mammary glands of wt and cyclin D2 -58 transgenic mice after normalization with actin. The four stars indicate undetectable levels of cyclin D2 in wt mammary glands during development p27 kip1 protein level was not significantly increased in the pregnant glands in either genotype, but declined during lactation in both wt and cyclin D2 transgenic mice (Figures 7 and 8) . At 10 days of involution, p27 kip1 protein level was re-elevated to a comparable level in both wt and cyclin D2 involuted mammary glands (Figure 7 ). These in vivo data suggest that upregulation of p27 kip1 may be downstream of cyclin D2 expression as was higher in the cyclin D2 mice at all stages of development compared to the wt. Furthermore, the increased p27 kip1 levels may be one of the causative factors in the increased apoptotic frequency detected in pregnant and involuting cyclin D2 mammary glands.
Cell cycle kinase activities in mammary epithelial cells overexpressing cyclin D2
In these experiments, we focused on stages of midpregnant and involution in comparison to 12-week virgin mammary glands in both groups. In mammary glands of virgin mice, cdk4 activity was weak in both wt and cyclin D2 mammary glands, while cdk2 activity was high in the mammary glands of both types of mice, but was twofold higher in the cyclin D2 compared to wt mammary gland (Figure 9a ). These data indicated that overexpression of cyclin D2 localized in the luminal epithelial cells induced a modest increase in cdk2 activity in the virgin mammary glands, which Figure 8 Localization and analysis of cyclin D2 and p27 kip1 protein levels by their total score in immunohistochemical staining. (a) Histologic sections of mammary glands derived from wt and cyclin D2 -58 mammary glands stained for cyclin D2 and p27 kip1 (406 magnification). (b) Total score of cyclin D2 and p27 kip1 were calculated from 3 -4 sections/group based on the intensity and number of positively stained cells as described in Materials and methods and presented in bar graph (+s.e.m.) The X indicates no cyclin D2 or p27 kip1 was scored correlated well with the 1.9-fold increase in cell proliferation ( Figure 5 ). In mid-pregnancy, where maximum cell proliferation and differentiation are taking place, the total cdk4 activity increased by 8.3-fold in the wt mammary glands while the activity in the cyclin D2 transgenics remained at the same levels when compared to virgin glands. The cdk2 activity increased modestly in the wt mammary gland, but still did not attain the high levels detected in the pregnant cyclin D2 mice (Figure 9a ). The total cdk4 activity is a culmination of three D-type cyclins-associated kinase activities, whereas the total cdk2 activity is resulting from the three D-type cyclins, E and A-associated kinase activities. The cdk4/cdk2 activity ratios were 1.88 and 0.17 in mammary glands of wt and cyclin D2 pregnant mice, respectively; 11-fold higher in wt glands. These data suggest that overexpression of cyclin D2 can reverse the wt cdk4/cdk2 ratio, which may have led to increases in BrdU incorporation rate in the cyclin D2 mammary epithelium of pregnant mice ( Figure 5 ). At 10-day involution, the level of cdk4 activity decreased modestly in the wt mammary glands and was maintained at low levels in the D2 transgenic mice compared to the levels during pregnancy in the same group. During involution, a profound difference of 4.4-fold in cdk4 activity was observed in the wt compared to cyclin D2 mammary glands (Figure 9a ). While cdk2 activity declined marginally at 10-day involution in the wt, the inhibition was more apparent (2.7-fold) in the cyclin D2 involuted mammary glands as compared to the level at mid-pregnancy. These data indicate that the cdk4/cdk2 ratio reversed to a similar pattern as in pregnancy: being 4.2-fold higher in wt as compared to cyclin D2 involuted mammary glands. Based on the finding that induction of cyclin D1 and/or cyclin D2 by myc contribute to cell cycle entry through a shift in p27 kip1 from cdk2 to cdk4 complexes in primary mouse embryo fibroblasts (Perez-Roger et al., 1999; Ravanko et al., 2000; Bouchard et al., 1999) , we examined whether the reversed cdk4/cdk2 activity ratio in the cyclin D2 mammary glands of pregnant mice was related to p27 kip1 sequestration by cdk4 complexes. Equivalent amounts of protein extracts from both groups of mammary glands were immunoprecipitated with either cdk4 or cdk2 antibodies followed by Western blot analysis of p27 kip1 protein associated to these cdks. In the virgin glands, the level of p27 kip1 -cdk4 was twofold higher in the cyclin D2 transgenic glands compared to wt and equally high in association to cdk2 in both lines. These data suggest that the increase in p27 kip1 in cdk4 complex in the virgin D2 mammary glands might be important for the twofold increase in cdk2 activity in the cyclin D2 virgin mammary gland (Figure 9a ). The increase in p27 kip1 complexed to cdk4 was more evident (two-and threefold) in virgin and pregnant mammary glands of cyclin D2 transgenic mice, respectively. With increased cyclin D2 protein levels in the transgenic cyclin D2 mice, the p27 kip1 protein was shifted from cdk2 to cdk4 complexes in the virgin and pregnant mammary glands, but was compartmentalized in both cdk4 and cdk2 in the involuted cyclin D2 mammary glands (Figure 9b ). This is in contrast to the situation in wt, where p27 kip1 was complexed with cdk2 and more obvious with cdk4 only during involution. The profound increases in p27
Kip1 in cdk4 and cdk2 complexes during involution may confirm the 30% increase in apoptotic activity in the D2 mammary glands (Figure 6 ). Therefore, this result indicates a preferential association of p27 kip1 to cyclin D2-cdk4 complexes in cells overexpressing cyclin D2 and to both kinases when cyclin D2 declines as in the D2 involuted mammary glands. kip1 shift between cdk4 and cdk2 complexes in wt and cyclin D2-58 mammary glands in pregnant and involution. (a) Equivalent amounts of 500 mg protein extracts were immunoprecipitated with antibodies against cdk4 or cdk2 for kinase activity analysis. The negative control was wt mammary gland of pregnant mice that was analysed without adding substrate. The substrates were Rb and Histone H1 proteins for cdk4 and cdk2 activity, respectively. The phosphorylated substrates were quantified with Molecular Dynamics SF densitometer as arbitrary units and averaged as presented in the bar graph (+s.e.m.). (b) Equivalent amounts of 500 mg protein extracts from individual mammary glands of wt and cyclin D2 -58 at indicated stage of development, were immunoprecipitated with antibodies against cdk4 or cdk2 and immunoblotted with mouse monoclonal antibody for p27 kip1 . In this experiment, lactating mammary glands were not analysed. The p27 kip1 associated with cdk4 or cdk2 were quantified, averaged and presented as bar graph (+s.e.m.). The stars indicate undetectable p27 kip1 in association to cdk4 or cdk2
We examined whether overexpression of cyclin D2 has an impact on mammary tumorigenesis. The tumor incidence in cyclin D2 -58 was four mammary carcinomas out of 21 mice (19%) with a latency of 12.5 months, while no tumors were developed in the wt during a period of 18 months. Hence, the long-term overexpression of cyclin D2 may have taken over the role of cyclin D1 to promote ductal epithelial cell proliferation. The effect of cyclin D2 overexpression on mammary alveologenesis during pregnancy is plausibly mediated through inhibition of cyclin D1 phosphorylation. The question is whether cyclin D1 has a role in D2 transgenic mice mammary tumorigenesis. The levels of cyclin D1 phosphorylation in relation to cyclin D2 levels in D2 transgenic mice mammary tumors are currently undergoing.
Discussion
One hallmark of the three D-type cyclin proteins is their ability to induce cell cycle entry and progression of resting cells when expressed in a deregulated manner. This study shows that overexpression of cyclin D2 results in dysregulation of normal mammary gland development and an increase in mammary tumorigenesis. Thus, cyclin D2, like cyclin D1 behaves as an oncogene for the mammary gland, however the role of cyclin D2 is not as critical as cyclin D1 for normal mammary gland development.
In this study, cyclin D2 was undetectable in wt mammary glands at all stages of development as measured by Western blot; however by immunohistochemistry, it was localized predominantly in the myoepithelial cells in the virgin gland suggesting that the luminal epithelial cells of the mammary glands can develop regardless of the absence of cyclin D2. This data is in agreement with other reports suggesting no specific mammary phenotype in the cyclin D2 knockout mice (Siciniski et al., 1996) . Although cyclin D2 was reported to be expressed in both myoepithelial and luminal epithelial cells at the RNA level in normal human breast samples (Evron et al., 2001) , our data in this study and those of others (Lukas et al., 1995) demonstrated that cyclin D2 protein was localized predominantly in the myoepithelial cells in the wt virgin mammary glands. However, a few cyclin D2 positive luminal epithelial cells were detected in every duct of the virgin mammary gland in the cyclin D2 transgenic mice. Because cyclin D2 was undetected in the luminal epithelial cells of wt mammary gland at all stages of development, it is conceivable to suggest that in the 'normal' mammary gland development, myoepithelial cell proliferation may depend on cyclin D2, while luminal epithelial cells may depend on cyclin D1. This interpretation does not exclude overexpression of cyclin D2 in the luminal epithelial cells in mammary tumors, as cyclins D1 and D2 were detected in mouse mammary tumors after overexpression of wnt-1 and myc genes (Yu et al., 2001) Overexpression of cyclin D2 targeted to the mammary gland resulted in altered morphogenesis that was most evident during pregnancy. It is apparent that the level of cyclin D2 overexpression localized in the luminal mammary epithelial cells coincided with the extent of altered morphogenesis in mammary gland in pregnant animals. For example, after analysis of cyclin D2 in mammary glands from multiple pregnant animals of wt, low expresser (D2 -58) and high expresser (D2 -53) mice, severe defects in alveologenesis were observed in mammary glands of the high cyclin D2 expresser (D2 -53). Mammary glands of low cyclin D2 expresser (D2 -58) were able to differentiate, and eventually managed to nurse their pups, but were still under-developed, apparent by the small size and number of the lobules and lobuloalveolar structures. These lobules were unable to expand in size during lactation and contained few secretory cells compared to the wt.
The molecular basis for the altered morphogenesis in pregnant D2 mice may be explained by the fivefold decrease in cyclin D1 phosphorylation which was concomitant with the 2.7-fold increase in cell proliferation and 2% increase in apoptosis. These alterations imply two mechanisms occurring in the mammary epithelial cell populations in pregnant cyclin D2 mice. First, the increase in cell proliferation is related directly to the overexpression of cyclin D2, but not cyclin D1 in the ductal cell population. Overexpression of cyclin D2 resulted in assembled p27 kip1 on cdk4 rendering it as an inactive complex. This is evident by the 16-fold increase in the p27 kip1 -cdk4/p27 kip1 -cdk2 ratio in pregnant cyclin D2 -58 compared to wt that allowed activation of cdk2 complexes to promote cell proliferation. These data are in agreement with a report demonstrating that activation of myc induced overexpression of cyclin D2 that rapidly up-regulated cyclin E-Cdk2 kinase activity and antagonizing association of p27 kip1 with cdk2 (Perez-Roger et al., 1999; Pajic et al., 2000) .
The second mechanism appears to take place in a cell population that is eligible for differentiation. Cyclin D1 was reported to be a critical molecule in lobuloalveolar development during pregnancy (Fantl et al., , 1999 and ablation of cyclin D1 was suggested to be a specific protection mechanism against breast cancer with activated Neu-Ras pathway (Yu et al., 2001) . However, these reports did not mention the importance of cyclin D1 phosphorylation in mammary gland alveologenesis and normal lobuloalveolar development. Because overexpression of cyclin D2 resulted in profound inhibition in cyclin D1 phosphorylation in pregnant glands of cyclin D2 -58 mice, it is possible that the expression level of cyclin D2 may correspond to the level of inhibition of cyclin D1 phosphorylation in mammary cell populations that are ready to differentiate. Thus, a higher cyclin D2 expresser (e.g. cyclin D2 -53) may possess a higher potential to completely inhibit cyclin D1 phosphorylation resulting in a greater block in alveologenesis than a lower cyclin D2 expressing line (cyclin D2 -58) as evidenced by the latter's limited lobuloalveolar development. Since the completion of lobuloalveolar development proceeds the start of lactation process, the inhibition of cyclin D1 phosphorylation in the wt lactating mammary glands confirmed the critical requirement for cyclin D1 hyperphosphorylated isoform to form active cyclin D1-cdks complexes that function in lobuloalveolar development. Previous reports on normal human fibroblasts have demonstrated that the soluble fraction (lower band) of cyclin D1 localized in the cytoplasm was tyrosine phosphorylated at early G1, while the insoluble fraction (upper band) was tyrosine and serine phosphorylated and was tightly bound to the nuclear structure during mid and late G1 (Scovassi et al., 1997) . In addition, human fibroblasts treated with protein kinase A inhibitor, staurosporine, induced cell cycle arrest at early G1 phase with strongly reduced cyclin D1 phosphorylation and a concomitant 60% reduction in the ratio of nuclear-bound/total cyclin D1 levels (Scovassi et al., 1997) . Therefore, our data indicate that the inhibition of cyclin D1 phosphorylation by cyclin D2 overexpression may be a critical factor in impeding the development of lobuloalveolar structures in the mammary glands of the D2 -53 and D2 -58 transgenic lines to a greater and lesser extent, respectively. It appears that overexpression of cyclin D2 in luminal mammary epithelial cells uncouples growth and cell proliferation. The mechanism of action of high levels of cyclin D2 may be involved in the inhibition of kinases responsible for phosphorylation of specific sites that are critical for cyclin D1 function in alveologenesis. Furthermore, it is conceivable to suggest that the lack of cyclin D2 expression by methylation of its promoter in a sub-group of human breast tumors (Evron et al., 2001 ) may be critical to fully permit cyclin D1 phosphorylation in breast tumors that express only cyclin D1 (Yu et al., 2001; Barnes and Gillett, 1998; Bartkova et al., 1994; Oyama et al., 1998) .
The 2% increase in apoptotic cells that was predominantly localized in the lobuloalveolar structures of pregnant cyclin D2 -58 mice may be a result of cells receiving two conflicting signals simultaneously; one to induce cell proliferation through cyclin D2 overexpression by the first mechanism of sequestration of p27 kip1 on cdk4 complexes and the other to induce cell differentiation, which is dependent upon the level of hyper-phosphorylated cyclin D1 isoform that is lacking in the cell populations that are capable of differentiation.
In conclusion, the overexpression of cyclin D2 induced cell proliferation in pregnant mammary glands through induction, sequestration and assembly of p27 kip1 on cdk4 leaving cdk2 complexes active. However, cyclin D2 overexpression also inhibited cyclin D1 phosphorylation in pregnant glands. The result was impeded normal alveologenesis, perhaps through elevated apoptosis in addition to the inhibition in cyclin D1 phosphorylation. In involution, despite similar levels of p27 kip1 that induced apoptosis in both wt and cyclin D2 transgenic line, cyclin D2 mammary glands showed acceleration in involution 10 days after weaning, perhaps due to the 30% (P40.005) increase in the apoptotic cells. Further study on cell apoptosis at earlier time-point during involution is warranted to confirm the rate of involution between wt and cyclin D2 mammary glands. Collectively, these data suggest that cyclin D2 has little role, if any, in normal mammary cell differentiation, but its overexpression in luminal mammary epithelial cells may impede cell alveologenesis and lobuloalveolar development. However it induces proliferation and in the long term it enhances mammary tumorigenesis.
Future work will utilize cyclin D2 transgenic mouse to study cyclin D1 phosphorylation in tumors that arise from these mice. Because cyclin D2 in addition to cyclin D1 expression occurs in a subset of human breast cancers, an examination of gene expression patterns in cyclin D2 expressing mammary tumors might yield targets for unique therapeutic intervention.
Materials and methods
Generation of cyclin D2 transgenic mice
The 1.2 kb full length mouse cyclin D2 cDNA in the blueScript SK vector was obtained from Dr Charles J Sherr at Department of Tumor Cell Biology, St Jude Children's Research Hospital, Memphis, TN, USA. The EcoRI 1.2 kb fragment of mouse cyclin D2 cDNA was cloned into the corresponding site in the MMTV-KCR-bGHpA transgenic vector to yield the MMTV-KCR-D2-bGHpA vector. The 2.334 kb BamHI MMTVLTR directs mammary gland specific expression (Sinn et al., 1987) . The BamHI-EcoRI KCR fragment was derived from the rabbit beta-globin gene fragment and included the partial Exon II, intron II and Exon III with the appropriate spice donors and acceptors and the polyadenylation signal was derived from the bovine growth hormone (bGH) gene. A NotI (blunt)-Acc65I MMTV-KCR-D2-bGHpA fragment was then cloned into the HindIII (blunt)-Acc65I sites of a PGK-Neo vector for stable transfection into HC11 cells by the lipofectamine protocol (GIBCO/Life Technologies). This resulting construct was verified for functionality by the production of functional cyclin D2 protein as detected by Western blot analysis. For microinjection, the 4.6 kb MMTV-KCR-D2-bGHpA transgenic fragment was released from vector sequences with XbaI and Acc65I, gel isolated and purified using Qiaex II beads according to manufacturer's instructions (Qiagen). This linearized fragment was then microinjected into fertilized FVB one-celled embryos using standard protocols at the transgenic core facility at Baylor College of Medicine, TX, USA.
Transgene DNA-polymerase chain reaction (PCR) and Southern blot analysis Genomic DNA was extracted from mouse's tail and used for PCR and Southern blot analysis to genotype the potential founders and their offsprings. We used reverse-KCR-D2 5'-TGCTTCCCTTACCTCCTTCC and forward-KCR-D2 5'-CTGCTAACCATGTTCATGCC primers together with forward-b-actin 5'-GATGTGCTCCAGGCTAAAGTT and reverse-b-actin 5'-AGAAACGGAATGTTGTGGAGT as internal control primers to screen for potential transgenic mouse lines. The PCR amplification renders 200 and 550 bp PCR products of cyclin D2 and b-actin, respectively. PCR was performed by denaturation at 948C for 2 min followed by 30 cycles of amplification as follows: denaturation at 948C for 1 min, annealing at 558C for 40 s, and extension at 728C for 40 s, with a final extension at 728C for 5 min.
For Southern blot analysis, a 640 bp BamHI-EcoRI KCR fragment was used as a probe to screen for potential founders by digesting 5 mg genomic tail DNAs with BglII and NcoI. An expected two main bands of 1253 and 2175 bp were observed that correspond to the transgenic signal. As positive control provides an approximate copy number of cyclin D2 incorporation in cyclin D2 mice, 10 and 100 pg of the MMTV-Cyc-D2 plasmid were digested with BglII and NcoI was included in the blot to represent approximately 1 and 10 copies, respectively. An expected 1.4 and 2.9 kb were detected that correspond to the digested plasmid bands.
Whole mount preparation
The inguinal (#4) mammary glands from both wt and cyclin D2 transgenic mice were removed and evaluated for morphological stage of development as whole mounts following protocol described earlier (Rasmussen et al., 2000) . The whole mounts were examined under 46 -106 power with a dissecting microscope.
Immunohistochemical analysis of cyclin D2, p27 kip1 and BrdU
Two hours before sacrifice, each animal received an i.p. injection of BrdU (70 mg of BrdUrd (Sigma Chemical Co.)/g body weight). After BrdUrd injection, the animals were killed, and both inguinal glands were dissected, carefully flattened, and fixed in cold 4% para-formaldehyde for 2 h and then postfixed in 70% ethanol. Fixed tissues were embedded in paraffin and sectioned (4 mm) for either standard H&E staining or BrdU, cyclin D2, or p27 kip1 immunohistochemical staining. Following the manufacturer's protocol in using the In-Situ Detection kit (PharMingen Inc.), localization of the positive BrdU-stained mammary epithelial cells was examined for each tissue section, and several random fields of 1000 cells were counted/section. For cyclin D2 and p27 kip1 immunohistochemical staining, after deparaffinization and hydration of the sections, the slides were blocked with 10% non-fat milk for 1 h before they were treated with primary antibody against cyclin D2 (M-20) or against p27 kip1 (M-197) (Santa Cruz Biotechnology Inc.) at a dilution of 1 : 400 and 1 : 100, respectively. The secondary biotinylated goat anti-rabbit or anti-mouse IgG, (Vector laboratories, Burlingame, CA, USA) was used at a dilution of 1 : 500 for 1 h at room temperature. Slides were then rinsed and incubated with avidin-biotin-peroxidase complex (ABC kit; Vector Laboratories) followed by 3, 3'-diaminobenzidine for color development (DAB kit; Zymed Laboratories, Inc.), rinsed and counterstained with 3% methyl green. The negative control for p27 kip1 was a section of p27 kip1 null mammary gland, while for the cyclin D2, nonimmune normal goat serum was substituted for the primary cyclin D2 antibody. Immunostained slides were scored as previously described based on intensity and number of positively stained cells (Harvey et al., 1999) . Briefly, using a light microscope, the first proportion score was based on the estimated proportion of positive-staining cells (0, none; 1, 51/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3 to 2/3; and 5, 42/3). Next, an intensity score was assigned based on the average intensity of positively stained cells (0, none; 1, weak; 2, intermediate; and 3, strong) . The proportion and intensity scores were then added to obtain a total score, which ranged from 0 to 8.
Western blot analysis, immunoprecipitation, and cdks activity assays
The mammary glands at the following stages of development: 12 week virgin, 14 -16 day pregnant, 10 day lactation and 10 day involution were removed from both wt and cyclin D2 transgenic mice and placed directly on dry ice for protein assays. Mammary glands from multiple animals at each stage-point were analysed for consistency of the results. Each protein sample was extracted from four mammary glands removed from a single animal at each stage-point and homogenized in chilled lysis buffer containing; 50 mM HEPES (pH 7.8), 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, and 0.1% Tween-20 supplemented with 0.1 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 20 units/ml aprotinin, 10 mM b-glycerophosphate, 1 mM NaF, and 0.1 mM sodium orthovanadate (all protease and phosphatase inhibitors were obtained from Sigma Chemical Co.). Cellular debris was removed after ultracentrifugation at 100 000 g for 1 h at 48C. The protein concentration of the supernatant was determined by the bicinchoninic acid protein assay (Pierce, Rockford, IL, USA).
For Western blot analysis of cyclin D1, D2, and p27 kip1 , equivalent amounts of protein (250 mg/sample) were separated on 12.5% denaturing gels, electroblotted onto nitrocellulose membranes, incubated with cyclin D rabbit polyclonal antibodies (Upstate Biotechnology Inc.), which detects both cyclin D1 and D2, or with p27 kip1 (F-8) mouse monoclonal antibody. After incubation for 1 h with horseradish peroxidase-conjugated secondary anti-mouse or antirabbit antibodies (Amersham Corp., Arlington Heights, IL, USA), the protein bands were detected by enhanced chemiluminescence kit (Amersham Corp.) or SuperSignal detection kit (Pierce Inc.) and quantified using PhosphoImager SP analyser (Molecular Dynamics Inc.).
The level of p27 kip1 associated to cdk4, cdk2 and cyclin E, and the cdk4/2 and cyclin E-associated kinase activities were determined by immunoprecipitation of equivalent amounts of protein extracts (500 mg/sample) with rabbit polyclonal antibodies against cdk4 (Santa Cruz), cdk2 or cyclin E (Upstate Biotechnology). Immune complexes were assayed for histone H1 or Rb kinase activity as described previously , except that proteins were transferred to nitrocellulose after SDS -PAGE to allow for Western blotting. After the blots were exposed to films for H1 or Rb protein phosphorylation, Western blotting was followed using p27 kip1 (F-8) mouse monoclonal antibody to detect the level of p27 kip1 in the immune complexes.
